Efficacy of intermittent low dose alendronate in Thai postmenopausal osteoporosis (Q44852221)

6 December 2017

Efficacy of intermittent low dose alendronate in Thai postmenopausal osteoporosis (English)

1 reference

6 December 2017

0 references

6

Rajata Rajatanavin

1 reference

6 December 2017

La-or Chailurkit

1

1 reference

6 December 2017

Srikorn Aunphongpuwanart

2

1 reference

6 December 2017

Boonsong Ongphiphadhanakul

3

1 reference

6 December 2017

Wallaya Jongjaroenprasert

4

1 reference

6 December 2017

Sunee Sae-tung

5

1 reference

6 December 2017

1 February 2004

1 reference

6 December 2017

1 reference

6 December 2017

30

1 reference

6 December 2017

1

1 reference

6 December 2017

29-36

1 reference

Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial

6 December 2017

1 reference

https://api.crossref.org/works/10.1081%2FERC-120028385

Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FERC-120028385

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FERC-120028385

Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FERC-120028385

Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FERC-120028385

Effect of alendronate on bone mineral density and bone turnover in Thai postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FERC-120028385

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FERC-120028385

Placebo-controlled multicenter study of oral alendronate in postmenopausal osteoporotic women. FOSIT-Study-Group. Fosamax International Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FERC-120028385

Guidelines for diagnosis and management of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FERC-120028385

Alendronate Prevents Postmenopausal Bone Loss in Women without Osteoporosis: A Double-Blind, Randomized, Controlled Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FERC-120028385

Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FERC-120028385

Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FERC-120028385

The efficacy and tolerability of alendronate in postmenopausal osteoporotic Chinese women: a randomized placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FERC-120028385

Alendronate prevents bone loss in Chinese women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FERC-120028385

A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. The Alendronate Phase III Osteoporosis Treatment Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FERC-120028385

Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FERC-120028385

Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FERC-120028385

Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FERC-120028385

21 January 2018

Identifiers

DOI

10.1081/ERC-120028385

1 reference

6 December 2017

1 reference